Genor Biopharma, a China-based drug developer that is engaged in development of a number of biosimilars, has completed a phase 1 study of a proposed infliximab biosimilar, GB242, referencing Remicade.
Genor Biopharma, a China-based drug developer that is engaged in development of a number of biosimilars targeting oncology and inflammatory indications, has completed a phase 1 study of a proposed infliximab biosimilar, GB242, referencing Remicade. Results of the study were published in BioDrugs.
The investigators conducted the randomized, double-blind, parallel-controlled study in 48 healthy subjects in a single center. The volunteers were assigned to receive either the proposed biosimilar or the reference infliximab at a dose of 3 mg/kg. Blood samples were collected to assess pharmacokinetics (PK) and immunogenicity, and safety was assessed throughout the study.
PK similarity was concluded if the 90% CIs for the geometric mean ratios of the biosimilar and the reference for maximum concentration (Cmax), area under the concentration—time curve (AUC) from time zero to the last quantifiable concentration (AUCt), and AUC from time zero to infinity (AUC∞) fell within the prespecified bioequivalence margin of 80% to 125%.
The authors report that the mean serum concentration—time curves were similar between the biosimilar and reference, and the 90% CIs for the geometric mean ratios of the 2 products for Cmax, AUCt, and AUC∞ were contained within the 80% to 125% margin, and therefore the products demonstrated bioequivalence.
The proportion of volunteers who experienced treatment-emergent adverse events was similar between the groups, as were antidrug antibody profiles.
According to the authors, the study showed high PK similarity between the proposed biosimilar and its reference, and the drugs showed similar safety and immunogenicity.
According to Genor, the proposed biosimilar product has now moved to phase 3 development.
Among the other biosimilars being developed by the company are GB221, a proposed trastuzumab in phase 3 development; GB232, a proposed adalimumab in phase 1 development with partners; GB222, a proposed bevacizumab entering phase 3 development; and GB241, a proposed rituximab in phase 1 development with partners.
Reference
Zhang T, Chen G, Liu C, et al. A phase 1 study comparing the pharmacokinetics, safety, and immunogenicity of proposed biosimilar GB242 and reference infliximab in healthy subjects. BioDrugs. 2019;33(1):93-100. doi: 10.1007/s40259-018-0326-x.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.